Hyku Biosciences is a company focused on improving patient lives by advancing the scientific boundaries of covalent medicines. The company is composed of diverse individuals working on pushing the limits of scientific research in the field of covalent medicines.

Hyku Biosciences

With a singular goal to improve patient lives, Hyku is pioneering precise covalent targeting of disease-causing proteins and transforming conventional treatment paradigms

Hyku Biosciences is pleased to announce that Dr. Kleem Chaudhary has come on board as our new President and CEO! We are excited for Kleem to lead us into the future as we develop novel therapeutics that address serious unmet needs of patients.

https://lnkd.in/ezgbfWew

Thank you so much BioCentury Inc. for the great write up! 

https://lnkd.in/eUJXEpSk

Thank you Endpoints News for a great interview with our CEO, Milind Deshpande, PhD., discussing our launch and vision!

https://lnkd.in/eDRjGpB3

We are excited to announce the launch of Hyku Biosciences with $56M in seed finance. Please see the press release below for more information:

https://lnkd.in/eFY8Cb_v

COM:HYKUBIOSCIENCES

Hyku Biosciences

name

homepage url

country

linkedin url

employee count

sector

industry

Description

investor of

Metrics